Biomarin Pharmaceutical Inc. - Registered Shares

NASDAQ:BMRN   3:59:59 PM EDT
91.46
+1.93 (+2.16%)
Products

Biomarin's Hemophilia A Gene Therapy Assessed To Provide Substantial Cost Savings Per Patient In Preliminary Independent Report

Published: 09/15/2022 12:55 GMT
Biomarin Pharmaceutical Inc. - Registered Shares (BMRN) - Biomarin's Gene Therapy for Adults With Severe Hemophilia A, Roctavian™ (valoctocogene Roxaparvovec), Assessed to Provide Substantial Cost Savings per Patient in a Preliminary Independent Report.
Biomarin Pharmaceutical Inc - Biologics License Application (bla) Resubmission to FDA on Track for End of September 2022.
Biomarin - Icer Base-case Model Report Results in $4 Million Savings Versus Emicizumab Prophylaxis per Patient Over a Lifetime.